Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00976404 · ClinicalTrials.gov registry record · Phase 2
Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir
A Phase 2 study of HIV Infection, sponsored by Robert L. Murphy.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 3
- Study locations
NCT00976404: Completed Phase 2 study of HIV Infection, sponsored by Robert L. Murphy.
NCT00976404 is a Phase 2 study of HIV Infection that has completed, run by Robert L. Murphy. The registered enrollment target is 28 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00976404, a Phase 2 study of HIV Infection, has completed, sponsored by Robert L. Murphy.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation. The hypothesis is that eradication is possible only if very potent antiretroviral drugs are delivered in conjunction with an immunomodulatory agent that simultaneously attack the viral reservoirs.
Conditions Studied
Interventions
- BIOLOGICAL DNA + HIV-rAd5 vaccine
- DRUG ART intensification (raltegravir)
- DRUG ART intensification (maraviroc)
Study Locations (3)
California
- University of California San Francisco - San Francisco
Illinois
- Northwestern University - Chicago
New York
- Cornell University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
What the finished NCT00976404 record still lists
NCT00976404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (88% lower).
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 3 interventions - of which DNA + HIV-rAd5 vaccine is the first listed.
NCT00976404 reports a single indexed study location in California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00976404 about?
NCT00976404 is a clinical study titled "Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir". The objective of this study is to discover a new approach in which human immunodeficiency virus (HIV) can be eradicated from an infected individual by intensified antiretroviral treatment coupled with immunomodulation. The hypothesis is that eradication is possible only if very potent antiretroviral...
What is the current status of trial NCT00976404?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2009-11. Estimated completion is 2014-06.
What conditions does trial NCT00976404 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT00976404?
The interventions under investigation include: DNA + HIV-rAd5 vaccine (BIOLOGICAL), ART intensification (raltegravir) (DRUG), ART intensification (maraviroc) (DRUG).
Who is sponsoring clinical trial NCT00976404?
This trial is sponsored by Robert L. Murphy, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00976404 being conducted?
This trial has 3 study locations across California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00976404's enrollment target sits among peer trials
28 56th of 73 higher than 18 of 73 other HIV Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
ACTIVE NOT RECRUITING · Phase 2
-
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
COMPLETED · Phase 2
-
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
COMPLETED · Phase 2
-
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia